US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Methenamine hippurate (brand name Cystohipp©) has been launched in Germany

EQL’s key product methenamine hippurate has now been launched in Germany by EQL’s license partner Dr Pfleger under the EQL-owned brand Cystohipp[©].Cystohipp© is the only methenamine hippurate product that is registered in Germany. German patients with recurrent urinary tract infections will now, for the first time, have access to an equivalent alternative to antibiotics—an alternative that does not increase the risk of developing antibiotic-resistant bacteria. Since 2024, methenamine hippurate is recommended by The European Association for Urology to reduce recurrent UTI episodes in woman.

Year-end Report April 2025 - March 2026

During the quarter, sales rose to SEK 120.2 million, an increase of 6% from SEK 113.3 million in the previous year. Growth for next year negatively impacted by launch delays, but long-term outlook unchanged.Comments from the CEO Fourth-quarter sales amounted to SEK 120.2 million (113.3) and OPEX totaled SEK 29.4 million (23.6), both in line with expectations. However, the gross margin of 28% (41%) was below expectations, mainly due to one-off items impacting gross profit by SEK 13 million. Logistics remained more challenging than antici pated due to geopolitical uncertainty, increasing

EQL Pharma in process of recruiting new Chief Supply Chain Officer (CSCO)

EQL Pharma is recruiting a new CSCO with a clear CMO/CDMO background. This means that the current Chief Supply Chain Officer (CSCO) Magnus Erreth will leave his position. Magnus has been active in EQL Pharma since 2024 and will remain in his role until mid June 2026 and ensure a stable handover.- We would like to thank Magnus for his efforts during his tenure with EQL Pharma, especially given the challenging supply environment. "I would like to thank Magnus for his efforts with EQL. We wish him all the best for the future," says Axel Schörling, CEO of EQL Pharma. The process to

Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2025/26

EQL Pharma AB (publ) will publish its year-end report for the fourth quarter, 2025/26, on Friday, May 8[th].At 10.00 (CET) 8[th] May, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. CEO and President Axel Schörling presents and comments on the year-end report. After the presentation, there is an opportunity to ask questions for those who participate. Use the following link to access the virtual meeting: https://tinyurl.com/4h7x4yxn Date and time May 8[th], 2026, at 10.00 (CET) the presentation starts.

Mellozzan® (melatonin) has been approved in Italy

EQL's key product Mellozzan® has now received Marketing Authorization approval from the health authority in Italy (AIFA), where it will be provided to patients by EQL's licensing partner Italfarmaco S.p.A.. The launch of Mellozzan® in Italy is expected in the end of fiscal year 2026/27 or early 2027/28.Italy will be the second greenfield market for Mellozzan, after Germany, where EQL, with the help of Italfarmaco’s local expertise and infrastructure, will build the brand and generate prescriptions. The response from doctors and patients in Germany has been very good and the EQL hopes for an

Nomination committee for the 2026 Annual General Meeting

In accordance with the instructions of the Nomination Committee in EQL Pharma, the Nomination Committee shall be convened by the Chairman of the Board and shall consist of a representative for each of the three largest shareholders in terms of votes who wish to appoint a Nomination Committee member. The composition of the Nomination Committee is based on shareholder statistics from Euroclear Sweden AB as of the last banking day in December and other reliable information on ownership that has been made known to the company at the same time.Based on the above, the Nomination Committee for the

Bulletin from the extraordinary general meeting in EQL Pharma AB on 3 February 2026

Today, on 3 February 2026, the extraordinary general meeting was held in EQL Pharma AB. A summary of the adopted resolution follows below.Resolution on implementation of a long-term incentive program The extraordinary general meeting resolved in accordance with the proposal from the board of directors to implement a long-term incentive program for two key employees based on issue of warrants.  The incentive program comprises a maximum of 220,000 warrants. Each warrant entitles the right to subscribe for one new share in the company at a subscription price per share corresponding to

Interim Report April – December 2025

During the quarter, sales rose to SEK 118.9 million, an increase of 29% from SEK 92.2 million in the previous year. This represents a new record quarter for EQLComments from the CEO The third quarter of 2025/26 marks a recovery for EQL Pharma. Sales growth of 29 percent and EBITDA grows by 44 percent. Gross and operating margins also strengthen to 42 and 21 percent, respectively. The majority of the stockouts from the second quarter have remained in the third. However, deliveries of Memprex have worked well, resulting in an overall stronger quarter. A gradually improved inventory

Invitation to presentation in connection with EQL Pharma's interim report, third quarter, 2025/26

EQL Pharma AB (publ) will publish its interim report for the third quarter, 2025/26, on Tuesday, February 3[rd].At 10.00 (CET) 4[th] February, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. CEO and President Axel Schörling presents and comments on the interim report. After the presentation, there is an opportunity to ask questions for those who participate. Use the following link to access the virtual meeting: https://tinyurl.com/mpmbyxxn Date and time February 4[th], 2026, at 10.00 (CET) the

Notice of extraordinary general meeting in EQL Pharma AB

The shareholders of EQL Pharma AB, Reg. No. 556713-3425, are hereby invited to the extraordinary general meeting to be held on Tuesday 3 February 2026 at 13.00 at the company’s premises at Stortorget 1 in Lund.Right to participate and notification Shareholders wishing to attend the meeting must: · be registered in the company’s share register kept by Euroclear Sweden AB as of Monday 26 January 2026, and · notify the company of their intention to participate in the meeting no later than Wednesday 28 January 2026 in writing by mail to EQL Pharma AB, Stortorget 1, SE-222 23 Lund.

EQL Pharma recruits Anne D Jensen as new Chief Sales Officer (CSO) and Carl Lindgren leaves his position as Chief Business Development Officer (CBDO)

As previously announced, EQL Pharma has decided to strengthen its abilities in international commercial affairs, as a part of its European expansion. The Company has recruited Anne D. Jensen for this role. Anne will join the team early March 2026 and the current Chief Commercial Officer, Alexander Brising, will, as previously announced, leave his position 31[st] December 2025. Additionally, Carl Lindgren will leave his position as CBDO in June 2026.Anne spent five years in the Boston Consulting Group (BCG)’s healthcare practice operating from the Los Angeles and Copenhagen offices. Since

EQL Pharma recruits Allan Sylvest Aasberg as new Chief Financial Officer (CFO)

EQL Pharma strengthens and re-organizes its Finance Function to put more emphasis on business control and capital allocation. Our current CFO, Anna Jönsson, will take on the role as Head of Accounting. Allan Sylvest Aasberg will join as new CFO early April 2026.Allan has almost 25 years of experience from various finance roles in different types of organizations. His experience includes accounting, business control, group reporting, M&A, COO and CFO positions in large and small companies. He has worked in listed environment, family owned and PE owned firms and is used to the highest

EQL Pharma AB (publ) publishes prospectus and applies for admission to trading of bonds on the corporate bond list of Nasdaq Stockholm

On 24 January 2025, EQL Pharma AB (publ) (the “Company”) issued senior secured bonds of SEK 350 million (the “Bonds”). The Bonds have been admitted to trading on the Transfer Market segment of Nasdaq First North Bond Market since 25 February 2025. In accordance with the terms and conditions of the Bonds, the Company has today submitted an application for admission to trading of the Bonds on the corporate bond list of Nasdaq Stockholm.The first day of trading in the Bonds on the corporate bond list of Nasdaq Stockholm is expected to be on or around 19 November 2025. In connection therewith,

Methenamine Hippurate (branded as Cystohipp©) have gained marketing approval in Germany

EQL's key product methenamine hippurate has now gained marketing approval by the Health Authorities in Germany, where it is to be provided to patients by EQL's license partner Dr Pfleger under the EQL owned brand Cystohipp[©]. Launch is planned for mid-2026Cystohipp[©] is the only methenamine hippurate product registered in Germany. German patients with recurrent urinary tract infections will now for the first time have access to an equivalent alternative to antibiotics. An alternative that does not increase the risk of developing antibiotic-resistant bacteria.  About Cystohipp[®]

Interim Report April – September 2025

A tough quarter for EQLComments from the CEO The second quarter of 2025/26 was marked by unforeseen delivery disruptions, resulting in sales growth of only 1%. The EBITDA margin, which was naturally affected as well, amounted to just 10%, as the company’s fixed cost base is adapted to a higher expected sales volume. On a more positive note, Mellozzan received marketing approval in Turkey and was launched in the United Kingdom. Sales growth for the full year 2025/26 is forecast at around 15%. The quarter’s delivery setbacks and their consequences are not expected to impact our long-term

Invitation to presentation in connection with EQL Pharma's interim report, second quarter, 2025/26

EQL Pharma AB (publ) will publish its interim report for the second quarter, 2025/26, on Wednesday, November 5[th], before stock markets open.At 10.00 (CET) 5[th] November, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. CEO and President Axel Schörling presents and comments on the interim report. After the presentation, there is an opportunity to ask questions for those who participate. Use the following link to access the virtual meeting: https://tinyurl.com/yke7b4rd Date and time November 5[th],

EQL Pharma in process of recruiting new Chief Commercial Officer (CCO)

EQL Pharma is recruiting a new CCO with an international background as part of its new five-year plan. This means that the current Chief Commercial Officer (CCO) Alexander Brising will leave his position. Alexander has been active in EQL Pharma since 2016 and will remain in his role until the end of December 2025 and ensure a stable handover.- We would like to thank Alexander for his efforts over all these years, especially within the company's commercial strategies where he has worked to ensure that the portfolio of pharmaceutical products reaches its full potential in the geographical

Mellozzan® (melatonin) launched in the UK

EQL's key product Mellozzan[®] (tablets) has now been launched in the UK by our partner Medice. Medice specialise in ADHD and have previously launched Mellozzan[®] successfully in Germany, among other countries. Unlike many other countries in Europe, there is already a growing use of melatonin to treat children with ADHD and sleep problems in the UK. The melatonin tablet market had a turnover of around £10.8 million in 2024, with a volume growth of 32% compared to 2023.Mellozzan[®] in the UK is expected to be expanded with the oral solution in 2026. The application is currently under review

Delivery delays mean that the second quarter and thus the full year 2025/26 will be weaker than expected

EQL Pharma has experienced delays in deliveries from several suppliers during the second quarter, resulting in lost sales during the quarter. Deliveries will come, but the lost sales cannot be made up for in the third and fourth quarters. Full-year results for the 2025/26 financial year are expected to be closer to 15 than 30 percent growth.The delivery delays have also led to postponements of launches that were supposed to take place in Q2. These will instead take place towards the end of Q3 or early in Q4. As a result of the delivery delays, EQL Pharma announces that sales in the

Mellozzan® (melatonin) approved in Turkey

EQL Pharma's key product Mellozzan® (tablets) has been approved for sale by the Turkish Medicines Agency. EQL's partner in Turkey, Abdi Ibrahim, will both manufacture and market Mellozzan® locally. Sales are expected to commence in the first half of 2026.EQL receives a single-digit royalty based on sales. Mellozzan® in Turkey is expected to be expanded with the oral solution in 2027. The application is currently under review by the Turkish Medicines Agency. Abdi Ibrahim has also submitted an application for approval of Mellozzan® (tablets and oral solution) in Kazakhstan. About

Exercise of warrants in EQL Pharma AB’s incentive programs

EQL Pharma AB (the ”Company“) today announces that two senior executives and one key employee in the Company have chosen to exercise 466,000 warrants in the Company’s outstanding incentive programs for subscription of a total of 466,000 new shares.The Company’s CEO as well as one senior executive and one key employee in the Company have chosen to make full use of the opportunity to subscribe for shares by exercise of warrants in the Company’s long-term incentive programs 2021/2025 I and 2021/2021 II, respectively, which were resolved by the annual general meeting in August 2021 and the

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe